About 

In his executive roles, Hugh has over 35 years research and development experience in the pharmaceutical and biotechnology industry.

---

From 1992 to 2000 Hugh was based in the United Kingdom as the Technical Director with Ipsen Limited a pharmaceutical company specialising in the research, development and manufacture of niche biopharmaceuticals.

Hugh returned to Australia in 2000 to join Faulding Pharmaceuticals (the predecessor of Mayne Pharma) and took on the position of Vice President, Global Pharma Research & Development.

With the acquisition of Mayne Pharma by Hospira (later acquired by Pfizer) in 2007 Hugh was appointed the Corporate Vice President, Global Pharma R&D and was based in offices in Chicago and Melbourne. Hugh was responsible for the research and development of generic and novel proprietary chemical and biological pharmaceuticals.

The global R&D group of product formulators, analytical chemists, project managers, regulatory affairs professionals and intellectual property lawyers successfully developed, registered and launched numerous injectable and oral products in the USA, Europe, Asia and other territories.

In 2009 Hugh Burrill teamed up with some of Australia’s leading prostate surgical and research specialists to form the company CCH Pharma Pty Ltd an oncology business focused on commercialising novel technologies for the treatment of hormone dependent cancers such as prostate, breast and ovarian.

During 2014/15 Hugh Burrill was an Executive Director of Optimus Life Science Pty Ltd (ABN 11 165 079 014) an emerging pharmaceutical business providing development and advisory services. 

From 2015 to 2022 Hugh was a Non-Executive Director of IDT Australia Ltd (ASX: IDT) a public Australian pharmaceutical manufacturing and specialty pharmaceutical business based in Boronia, Victoria, Australia. Hugh was the Chair of the Audit and Risk Committee and a member of the Remunerations and Nominations Committee. 

IDT develops and manufactures pharmaceutical products, including medicinal cannabis and high potency products, for local and international clients. Its facilities are cGMP compliant and regularly audited by the US FDA and Australian TGA. IDT provides new drug development and scale-up, and commercial manufacture of active pharmaceutical ingredients (APIs) as well as a variety of oral and injectable finished drug dose forms. 

From 2007 to 2020 Hugh was Non-Executive Director and former Deputy Chair of Nova Aerospace Pty Ltd (ABN 11 090 818 214; trading as Nova Systems) an international professional services organisation addressing complex technical and management challenges in defence, transport, utilities, energy and communications. Nova employs over 600 specialist consultants across Australia, New Zealand, Singapore and the United Kingdom.

From 2009 to 2014 Hugh provided consulting services including strategic, management, product development and project leadership - particularly where the integration of product development, regulatory and intellectual property strategies are the key to success.
In addition, Hugh undertook due diligence on new products and businesses, and provided linkages to experts and potential partners.

............
Hugh has been a member of the Industry Development Taskforce of the Australian Pharmaceutical Industry Council, a foundation member of Biotech industry association AusBiotech, a member of the Williamson Leadership Group of Victoria and a member of Melbourne Forum.

Hugh earned his Bachelor and Master degrees in Science (Biotechnology) from the University of Queensland, an MBA from the University of Melbourne and is a Fellow of the Australian Institute of Company Directors.